ImmunoSPECT imaging shows that the effectiveness of a newly developed radioimmunotherapy for treating a resistant form of kidney cancer could be diminished when used after another anti-cancer therapy.
ImmunoSPECT imaging shows that the effectiveness of a newly developed radioimmunotherapy for treating a resistant form of kidney cancer could be diminished when used after another anti-cancer therapy, researchers found.
The therapy, radiolabeled monoclonal antibody girentuximab (cG250), has been shown to kill the cancer by delivering radiation directly, but it may not be as effective if it is preceded by treatment with sorafenib or similar tyrosine kinase inhibitors (TKIs), according to a study presented at the Society of Nuclear Medicine’s 2012 Annual Meeting, in Miami Beach, Fla.
Researchers from Radboud University Nijmegen Medical Center in Nijmegen, the Netherlands, recruited 15 patients with renal masses to participate to evaluate the effect of TKIs on the targeting of In-111-cG250 in patients with clear cell renal carcinoma. Of the 15 patients, 13 had clear cell renal carcinoma and 10 were also treated with sorafenib.
The patients underwent immunoSPECT imaging, using In-111-cG250 at the start of the study. The 10 patients who took sorafenib were imaged again after completing treatment. The results showed that the 10 patients who received sorafenib had remarkably lower targeting of In-111-cG250 to their tumors. This suggests that imaging and radioimmunotherapy with cG250 drug compounds should begin before treatments with sorafenib or similar TKIs, noted the researchers.
“This research has important implications for future therapeutic regimens for patients with clear cell renal carcinoma,” said Stijn Muselaers, MD, lead physician of the study. “This study indicates that imaging and therapy of tumors with radiolabeled antibodies could be hampered in patients that are being treated with TKIs such as sorafenib. This informs clinicals about the most appropriate sequence of treatments for patients with clear cell renal carcinoma in order to improve the care and potential survival for these patients.”
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.